

(19)



(11)

**EP 1 829 550 A2**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:

05.09.2007 Bulletin 2007/36

(21) Application number: 07006886.1

(22) Date of filing: 25.09.1997

(51) Int Cl.:

*A61K 38/00* (2006.01)*A61K 38/02* (2006.01)*A61K 38/36* (2006.01)*A61K 39/395* (2006.01)*C07K 14/00* (2006.01)*C07K 14/745* (2006.01)*C07K 16/18* (2006.01)*G01N 33/50* (2006.01)*A61K 33/00* (2006.01)*A61K 38/17* (2006.01)*A61K 38/48* (2006.01)*C07K 5/00* (2006.01)*C07K 14/435* (2006.01)*C07K 16/00* (2006.01)*C07K 16/28* (2006.01)

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE

(30) Priority: 27.09.1996 US 721447

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:

97944453.6 / 0 951 292

(71) Applicant: The Trustees of Columbia University in  
the City of

New York

New York, NY 10027-6699 (US)

(72) Inventors:

• Pinsky, David J.

48105, Michigan (US)

• Stern, David

30910, Georgia (US)

• Prestigiacomo, Charles J.

07936, New Jersey (US)

(74) Representative: Vossius &amp; Partner

Siebertstrasse 4

81675 München (DE)

Remarks:

This application was filed on 02 - 04 - 2007 as a  
divisional application to the application mentioned  
under INID code 62.

(54) **Methods for treating an Ischemic disorder and improving stroke outcome**

(57) The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selection antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a

sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

Applicants: David J. Pinsky et al.

Serial No.: 10/679,135

Filed: October 3, 2003

Exhibit 3

EP 1 829 550 A2